glp-1 trials near me receptor agonists are increasingly used to treat type 2 diabetes and obesity, and have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal New GLP-1 alternative, eloralintide, leads

Matfin G, Van BK, Zimmermann AG, Threlkeld R, Ignaut DA

Delilahs offerings look competitive at first glance, but without the up-front detail other clinics provide, it falls short on transparency and trust

Extended-release naltrexone/bupropion (Contrave, Currax Pharmaceuticals) was approved by the FDA in 2014 for chronic weight management in people with overweight or obesity

01 Consistency by batch Compounds are produced with consistency and traceability in mind from release to release

Their results, recently published in the journal Endocrinology, Diabetes & Metabolism , showed there may be a lowered risk of glaucoma in some circumstances